Medexus Pharmaceuticals Inc News - MDP

Medexus Pharmaceuticals Schedules First Quarter Fiscal 2020 Conference Call

MONTREAL, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV:...

Medexus Announces DTC Eligibility of its Common Shares in the United States

MONTREAL, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV:...

Medexus Pharmaceuticals Announces Operating and Financial Results for Fourth Quarter and Full Fiscal Year Ended March 31, 201...

Generated $2.4 million of Adjusted EBITDA for fiscal year 2019 Medexus management to host conference call at...

Medexus Pharmaceuticals Schedules Fourth Quarter and Fiscal 2019 Conference Call

MONTREAL, June 28, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV:...

Medexus Appoints Accomplished Global Pharmaceutical Industry Executive Adele M. Gulfo to its Board of Directors

MONTREAL, June 25, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV:...

Medexus Pharmaceuticals Announces Normal Course Issuer Bid

MONTREAL, Quebec, May 14, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company”) (TSXV: MDP...

Medexus Pharmaceuticals Launches New Metoject® Subcutaneous 15mg Dosage for the Treatment of Rheumatoid Arthritis, Psoriasis...

MONTREAL, May 07, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV:...

Medexus CEO to Present at Two Upcoming Investor Conferences

MONTREAL, April 23, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”...

Medexus Granted Authorization by Health Canada to Distribute Treosulfan in Canada

Commences shipments to hospitals under the Special Access Program Plans underway to apply for full...

Medexus Enters into Expanded Licensing Agreement for Gliolan® in Canada

MONTREAL, March 04, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”...

Medexus Pharmaceuticals Announces 512% Increase in Revenue to $14.4 Million for the Third Quarter of Fiscal 2019

Generates $2.2 million of Adjusted EBITDA Medexus management to host conference call at 4:30 PM ET today...

Medexus Pharmaceuticals Schedules Third Quarter Fiscal 2019 Conference Call

Retains Crescendo Communications for Investor Relations Services Conference call to be held at 4:30 PM...

Medexus Lists October 2018 Unsecured Convertible Debentures on the TSX Venture Exchange

MONTREAL, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the...

Medexus Files Business Acquisition Report

MONTREAL, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the “Company”) (TSXV: MDP, OTCQB: PDDPF...

Meredith Corporation to Record Special Charge

DES MOINES, Iowa, Jan. 14 /PRNewswire-FirstCall/ -- Meredith Corporation (NYSE:MDP) said today that it will record a special charge of...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Medexus Pharmaceuticals Inc (MDP)

Empower your portfolio: Real-time discussions and actionable trading ideas.

MDP News

Medexus Pharmaceuticals Schedules First Quarter Fiscal 2020 Conference Call

Medexus Announces DTC Eligibility of its Common Shares in the United States

Medexus Pharmaceuticals Announces Operating and Financial Results for Fourth Quarter and Full Fiscal Year Ended March 31, 201...

Medexus Pharmaceuticals Schedules Fourth Quarter and Fiscal 2019 Conference Call

Medexus Appoints Accomplished Global Pharmaceutical Industry Executive Adele M. Gulfo to its Board of Directors

Medexus Pharmaceuticals Announces Normal Course Issuer Bid

Medexus Pharmaceuticals Launches New Metoject® Subcutaneous 15mg Dosage for the Treatment of Rheumatoid Arthritis, Psoriasis...

Medexus CEO to Present at Two Upcoming Investor Conferences

Medexus Granted Authorization by Health Canada to Distribute Treosulfan in Canada

Medexus Enters into Expanded Licensing Agreement for Gliolan® in Canada

Medexus Pharmaceuticals Announces 512% Increase in Revenue to $14.4 Million for the Third Quarter of Fiscal 2019

Medexus Pharmaceuticals Schedules Third Quarter Fiscal 2019 Conference Call

Medexus Lists October 2018 Unsecured Convertible Debentures on the TSX Venture Exchange

Medexus Files Business Acquisition Report

Meredith Corporation to Record Special Charge

MDP Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Medexus Pharmaceuticals Inc (MDP) News

Medexus Pharmaceuticals Inc (MDP)

Empower your portfolio: Real-time discussions and actionable trading ideas.

MDP News

Medexus Pharmaceuticals Schedules First Quarter Fiscal 2020 Conference Call

Medexus Announces DTC Eligibility of its Common Shares in the United States

Medexus Pharmaceuticals Announces Operating and Financial Results for Fourth Quarter and Full Fiscal Year Ended March 31, 201...

Medexus Pharmaceuticals Schedules Fourth Quarter and Fiscal 2019 Conference Call

Medexus Appoints Accomplished Global Pharmaceutical Industry Executive Adele M. Gulfo to its Board of Directors

Medexus Pharmaceuticals Announces Normal Course Issuer Bid

Medexus Pharmaceuticals Launches New Metoject® Subcutaneous 15mg Dosage for the Treatment of Rheumatoid Arthritis, Psoriasis...

Medexus CEO to Present at Two Upcoming Investor Conferences

Medexus Granted Authorization by Health Canada to Distribute Treosulfan in Canada

Medexus Enters into Expanded Licensing Agreement for Gliolan® in Canada

Medexus Pharmaceuticals Announces 512% Increase in Revenue to $14.4 Million for the Third Quarter of Fiscal 2019

Medexus Pharmaceuticals Schedules Third Quarter Fiscal 2019 Conference Call

Medexus Lists October 2018 Unsecured Convertible Debentures on the TSX Venture Exchange

Medexus Files Business Acquisition Report

Meredith Corporation to Record Special Charge

MDP Discussion

Your Recent History